Form 4: CRISPR Therapeutics Director Rommel Christian Acquires Stock Options
SEC Form 4 Filing
Director Rommel Christian of CRISPR Therapeutics AG reports acquisition of stock options.
Summary
- On May 30, 2024, Rommel Christian, a director of CRISPR Therapeutics AG, acquired stock options for 26,000 common shares.
- The exercise price of these options is $54.06 per share.
- The options vest in 36 equal monthly installments starting June 30, 2024, and expire on May 30, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, which is neither overtly positive nor negative.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director could potentially increase shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| 05/30/2024 | Date of transaction: Rommel Christian acquired stock options. |
| 05/30/2024 | Stock option grant date. |
| 06/30/2024 | First vesting date for the stock options. |
| 05/30/2034 | Expiration date of the stock options. |
| 05/31/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.